Dermatology Xagena
Aggiornamento in Medicina
The results of a phase I study in advanced melanoma suggested complementary clinical activity with Nivolumab ( Opdivo ), a PD-1 checkpoint inhibitor, plus Ipilimumab ( Yervoy ), a CTLA-4 checkpoint in ...